Indication · Cardiology
Stroke prevention in atrial fibrillation
Last checked: Nov 20, 2026Source: FDA, ClinicalTrials.gov
Devices
52
Cleared or approved since 2000
PMA and De Novo
6
Higher-risk or first-of-kind devices
Breakthrough devices
0
Authorized through June 30, 2026
Recruiting device trials
29
159 device trials in all
Devices
46 devices via 510(k). PMA and De Novo devices first, then devices with the most FDA decisions. Each opens a full summary.
- microINR System
Iline Microsystems, S.L. · 510(k) · Test, Time, Prothrombin · newest 2025 · 5 decisions
45 more devices with a free account
Device trials
Device studies on ClinicalTrials.gov for this condition, any status, newest update first.
- Elite AF IDE Trial (Elite AF)Recruiting
Boston Scientific CorporationPublic (BSX)
NCT07287436 · 400 participants (planned) · Start Sep 18, 2026 · Primary completion Jan 2028
Device: WATCHMAN Elite LAAC Device · For: Atrial Fibrillation (AF); Stroke
Sites: Jonesboro, Arkansas; Santa Monica, California; Rochester, Minnesota · 5 sites in all
158 more trials with a free account
Device types
FDA product codes mapped to this indication. The mapping was made with AI help and may include a few loose fits.
Research
- Device studies on left atrial appendage across PubMed, Europe PMC and OpenAlex
- PubMed ↗
- Google Scholar ↗
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.